Evaluation of efficacy and safety of NRL/2019/NL in Liver Disorder Patients with Abnormal Liver Function Test (LFT) A randomized, parallel arm, interventional, prospective clinical study. - NI

etsurf Communications Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Males or females 18-65 years of age
•Diagnosis of hepatic disorder with abnormal LFT with or without signs and symptoms such as dark-colored urine, light-colored stools, pruritus, pruritic red hives, fever, nausea, vomiting, anorexia, and right upper abdominal discomfort, pain
•Subjects with or without fatty liver changes observed in Ultrasonography of abdomen will be enrolled in the study
•Serum total bilirubin level less than or equal to 2 mg/dl, or AST or ALT 2 times than normal values
•Subjects willing to sign inform consent form

•Evidence of chronic viral hepatitis (Hepatitis B or C) and Biliary obstruction
•Previous entry into the study, or use of either prednisolone or PTX within 6 weeks of admission
•AST >500 U/L or ALT >300 U/L
•Suspected hypersensitivity to contents of study drug
•Advanced liver disease, subjects with serious illness
•History of gastritis, peptic ulcer, bleeding ulcer
•Patients with a renal failure
•Pregnant or lactating women
•Other conditions, which in the opinion of the investigators, makes the patient unsuitable for enrollment

发起方

etsurf Communications Pvt Ltd